> top > docs > PubMed:33161369 > annotations

PubMed:33161369 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 37-40 Body_part denotes IgM http://purl.org/sig/ont/fma/fma62873
T2 45-48 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T3 139-147 Body_part denotes Antibody http://purl.org/sig/ont/fma/fma62871
T4 503-506 Body_part denotes IgM http://purl.org/sig/ont/fma/fma62873
T5 511-514 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T6 567-575 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T7 686-689 Body_part denotes IgM http://purl.org/sig/ont/fma/fma62873
T8 706-709 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T9 733-738 Body_part denotes serum http://purl.org/sig/ont/fma/fma63083
T10 772-777 Body_part denotes serum http://purl.org/sig/ont/fma/fma63083
T11 910-913 Body_part denotes IgM http://purl.org/sig/ont/fma/fma62873
T12 1067-1070 Body_part denotes IgM http://purl.org/sig/ont/fma/fma62873
T13 1099-1102 Body_part denotes IgM http://purl.org/sig/ont/fma/fma62873
T14 1259-1262 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T15 1435-1438 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T16 1534-1537 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T17 1662-1665 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T18 1759-1762 Body_part denotes IgM http://purl.org/sig/ont/fma/fma62873
T19 1829-1832 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T20 1995-1998 Body_part denotes IgM http://purl.org/sig/ont/fma/fma62873
T21 2003-2006 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 733-738 Body_part denotes serum http://purl.obolibrary.org/obo/UBERON_0001977
T2 772-777 Body_part denotes serum http://purl.obolibrary.org/obo/UBERON_0001977

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 81-89 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T2 229-237 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T3 264-272 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T4 492-500 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T5 600-608 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T6 724-732 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T7 899-907 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T8 1248-1256 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T9 1506-1515 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T10 1777-1785 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T11 1963-1971 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T12 1974-1983 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T13 2055-2063 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 148-155 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T2 156-159 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T3 427-437 http://purl.obolibrary.org/obo/BFO_0000030 denotes OBJECTIVES
T4 875-879 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T5 1000-1003 http://purl.obolibrary.org/obo/CLO_0053799 denotes 4-5
T6 1016-1020 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T7 1128-1131 http://purl.obolibrary.org/obo/CLO_0053799 denotes 4-5
T8 1368-1371 http://purl.obolibrary.org/obo/CLO_0053799 denotes 4-5
T9 1384-1388 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T10 1517-1518 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T11 1675-1678 http://purl.obolibrary.org/obo/CLO_0001313 denotes 3-6
T12 1844-1849 http://purl.obolibrary.org/obo/UBERON_0000473 denotes tests
T13 1936-1940 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T14 1961-1962 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T15 2040-2041 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
2 81-89 Disease denotes COVID-19 MESH:C000657245
3 90-98 Species denotes patients Tax:9606
19 229-239 Species denotes SARS-CoV-2 Tax:2697049
20 264-272 Disease denotes COVID-19 MESH:C000657245
21 492-502 Species denotes SARS-CoV-2 Tax:2697049
22 600-608 Disease denotes COVID-19 MESH:C000657245
23 609-617 Species denotes patients Tax:9606
24 724-732 Disease denotes COVID-19 MESH:C000657245
25 899-909 Species denotes SARS-CoV-2 Tax:2697049
26 1248-1258 Species denotes SARS-CoV-2 Tax:2697049
27 1506-1515 Disease denotes infection MESH:D007239
28 1560-1568 Species denotes patients Tax:9606
29 1638-1645 Species denotes patient Tax:9606
30 1777-1787 Species denotes SARS-CoV-2 Tax:2697049
31 1923-1931 Species denotes patients Tax:9606
32 1963-1983 Disease denotes SARS-CoV-2 infection MESH:C000657245
33 2055-2063 Disease denotes COVID-19 MESH:C000657245

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-126 Sentence denotes Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect.
T2 127-138 Sentence denotes BACKGROUND:
T3 139-273 Sentence denotes Antibody testing has recently emerged as an option to assist with determining exposure to SARS-CoV-2, the causative agent of COVID-19.
T4 274-426 Sentence denotes Elucidation of the kinetics and duration of the humoral response is important for clinical management and interpreting results from serological surveys.
T5 427-438 Sentence denotes OBJECTIVES:
T6 439-618 Sentence denotes Here we evaluated the clinical performance of Abbott SARS-CoV-2 IgM and IgG assays, as well as the longitudinal dynamics of the antibody response in symptomatic COVID-19 patients.
T7 619-644 Sentence denotes STUDY DESIGN AND RESULTS:
T8 645-749 Sentence denotes The diagnostic specificity was 100 % for IgM and 99.67 % for IgG using 300 pre-COVID-19 serum specimens.
T9 750-1034 Sentence denotes Using 1349 sequential serum samples collected up to 168 days post symptom onset from 427 PCR-confirmed individuals, clinical test sensitivity of the SARS-CoV-2 IgM assay was 24.6 % at ≤7 days, 75.3 % at 8-14 days, 95.0 % at 15-21 days, and 96.0 % at 4-5 weeks (peak test sensitivity).
T10 1035-1098 Sentence denotes The median duration of time for IgM seroconversion was 10 days.
T11 1099-1212 Sentence denotes IgM levels declined steadily 4-5 weeks after symptom onset, and the positive rate dropped to 30.8 % at >3 months.
T12 1213-1402 Sentence denotes The diagnostic sensitivity for the SARS-CoV-2 IgG assay post symptom onset was 23.2 % at ≤7 days, 69.5 % at 8-14 days, 93.6 % at 15-21 days, and 99.6 % at 4-5 weeks (peak test sensitivity).
T13 1403-1468 Sentence denotes The median duration of time for IgG seroconversion was 11.5 days.
T14 1469-1601 Sentence denotes During the convalescent phase of the infection, a decline in the IgG level was observed in patients who were followed for >100 days.
T15 1602-1710 Sentence denotes Despite that decline, 92.3 % of the patient cohort remained IgG positive 3-6 months following symptom onset.
T16 1711-1723 Sentence denotes CONCLUSIONS:
T17 1724-1907 Sentence denotes This study demonstrates the Abbott IgM assay against SARS-CoV-2 is detected slightly earlier compared to IgG, with both tests exhibiting excellent overall sensitivity and specificity.
T18 1908-2064 Sentence denotes In symptomatic patients who test negative by PCR for a SARS-CoV-2 infection, assessing IgM and IgG antibodies can aid in supporting a diagnosis of COVID-19.